Salomé Pinho developed her PhD research at the Institute of Molecular Pathology and Immunology of University of Porto, Portugal (IPATIMUP) and at Boston University School of Medicine (BU), MA, USA from 2006 to 2009. She performed her postdoctoral work at University of Porto in the glycobiology and glyco-immunology fields. Presently, she is a Principal Investigator and Group leader at i3S-Institute for Research and Innovation in Health at University of Porto, Portugal and Professor at Faculty of Medicine at University of Porto. The goal of Pinho lab is to disentangle the spatiotemporal regulation of glycans in the glycocalyx in health and disease and to decipher its biological information to better understand its impact in defining the magnitude, the nature and the fate of the immune responses associated with chronic inflammation, autoimmunity and cancer envisioning novel prognostic, diagnostic, and therapeutic strategies applied to major diseases including Inflammatory Bowel Disease and other IMIDs as well as in cancer. She is author of several publications in international peer-reviewed journals including Nature Reviews Cancer, Nature Immunology, Nature Reviews Gastroenterology & Hepatology, Gastroenterology, Science Translational Medicine, PNAS among many others. She has been awarded with prestigious grants funded by the Horizon Europe, European Research Council (ERC) and the US Department of Defense (among others), and has been receiving important awards and distinctions such as the Young Investigator Award from the European Association for Cancer Research (2012), The Pfizer award in Clinical research (2021) and the Glycobiology Significant Achievement Award (2020) by the American Society of Glycobiology, among other prizes and distinctions. She is currently the Vice-President of Portuguese Society of Immunology.

Paula Videira is the leader of the Glycoimmunology Research Group at UCIBIO and an Full Professor in Glycobiology and Immunology at the Life Sciences Department of NOVA School of Science and Technology, Universidade NOVA de Lisboa (NOVA‑FCT). Her work is driven by a strong commitment to understanding the complex roles of glycans in disease and translating Glycosciences into innovative, patient‑centered immunotherapies. Her research focuses on aberrant sialylated short O-glycans in cancer, glycan-mediated immune regulation, immunity and therapies for congenital disorders of glycosylation (CDG), and anti‑glycan antibodies. Paula has published extensively, secured major European and industry-funded grants, and co‑founded impactful initiatives including CDG&Allies‑PPAIN and the biopharmaceutical companies CellmAbs and Valvian. She has contributed to scientific governance in Europe, serves on editorial boards, and regularly organizes international courses. Her multidisciplinary research integrates cutting-edge assays, omics, bioinformatics, and patient-centric approaches to drive glyco‑immunology innovations toward clinical benefit.